Journal of Vaccines & Vaccination

Vaccination in the newborn age � our experience and dilemmas

2^nd International Conference on Vaccines and Vaccination

August 20-22, 2012 Hilton Chicago/Northbrook, USA

Zora Zakanj

Posters: J Vaccines Vaccin

Abstract:

V accine science has extended beyond genomics and proteomics to also encompass �immunomics�, the study of the universe of pathogen-derived or neoplasm-derived peptides that interface with B and T cells of the host immune system. It has been theorized that effective vaccines can be developed using the minimum essential subset of T and B-cell epitopes that comprise the �immunome�. We and other researchers are therefore using bioinformatics sequence analysis tools, epitope-mapping tools, microarrays and high-throughput immunology assays to discover the minimal essential components of the immunome beginning with genomic data. The genome-to-vaccine strategy may have a significant advantage over conventional vaccines, as careful selection of vaccine components may diminish undesired side effects as have been observed with whole pathogen and protein subunit vaccines. New approaches to improving vaccine safety and efficacy are needed to prevent and treat current and future infectious diseases as well as potential biothreat agents. The genome-to-vaccine strategy to produce epitope-based vaccines is a novel approach that addresses these needs and is technologically advancing steadily toward licensure of this new vaccine class. This presentation will bring to the fore the critical parameters thatvaccine developers need to know to harness genomic data to rapidly progress from pre-clinical testing to clinical trialsdrawing upon examples from our genomes-to-vaccine approach to biodefense (Smallpox, Tularemia, EEV) and emerging infectious diseases (pandemic flu).

Biography :

Prashant Sharma completed his Masters in biosciences from Bhopal University in 2007. He is working in The International Vaccine Institute (IVI) in Seoul, Korea, which is an international organization devoted to development and introduction of new and improved vaccines for the world?s poorest people before joining IVI, he worked in leading biotech companies in India. He was involved in the projects related to development of many viral and bacterial vaccines which include live and Inactivated two-way ,three-way and four way Animal vaccines, and the development of swine flu, Seasonal flu, Universal flu vaccine and candidate chimeric live tetravalent vaccine against Dengue subtypes